iBio, Inc. 10-Q Summary
Business Context and Reporting Period
iBio, Inc. is a preclinical biotechnology company developing AI-enabled precision antibodies. The company has transitioned away from its contract development and manufacturing organization (CDMO) business and is focused on its AI drug-discovery platform, including epitope steering, StableHu, EngageTx and ShieldTx technologies. The report covers the three months ended September 30, 2023, the first quarter of fiscal 2024, and was filed November 14, 2023.
Principal programs include IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8 and an autoimmune PD-1 agonist program. All programs remain preclinical or discovery-stage. Management expects to advance IBIO-101 toward an IND filing in calendar 2025.
Key Financial Metrics
| Metric | Q1 FY2024 | Q1 FY2023 | Change |
|---|---|---|---|
| Revenue | $50,000 | $0 | New license revenue |
| Research and development expense | $1.606 million | $2.548 million | Down $0.942 million |
| General and administrative expense | $3.547 million | $5.088 million | Down $1.541 million |
| Total operating expenses | $5.153 million | $7.636 million | Down $2.483 million |
| Operating loss | $5.103 million | $7.636 million | Improved $2.533 million |
| Loss from continuing operations | $5.074 million | $7.537 million | Improved $2.463 million |
| Loss from discontinued operations | $672,000 | $10.593 million | Improved $9.921 million |
| Net loss | $5.746 million | $18.130 million | Improved $12.384 million |
| Basic and diluted loss per share | $0.24 | $2.05 | Improved |
| Weighted-average shares | 23.969 million | 8.842 million | Increased substantially |
Revenue was immaterial relative to operating costs; therefore, meaningful operating or net profit margins were not established. The company remains loss-making and has generated significant accumulated losses.
- Net cash used in operating activities was $5.340 million, compared with $13.959 million in the prior-year quarter.
- Investing activities provided $50,000, primarily from fixed-asset sale proceeds.
- Financing activities provided $2.472 million, including $2.896 million from common-stock sales, partly offset by debt, lease and capital-raising payments.
- Cash, cash equivalents and restricted cash declined to $4.761 million at September 30, 2023, from $7.579 million at June 30, 2023. Unrestricted cash and cash equivalents were $1.461 million; approximately $3.3 million was restricted.
- Total assets were $37.678 million and total liabilities were $24.469 million at September 30, 2023.
- Stockholders’ equity was $13.209 million, down from $15.381 million at June 30, 2023.
- The term loan had a carrying balance of $12.625 million, net of deferred financing costs, at September 30, 2023. The equipment financing balance was $362,000, in addition to finance and operating lease obligations.
- Accumulated deficit was $294.686 million at September 30, 2023.
Material Changes Versus the Prior Comparable Period
- Continuing-operation revenue increased from zero to $50,000 due to recognition of a non-refundable license fee.
- R&D and G&A expenses declined primarily because of lower personnel, consulting and outside-service costs and increased performance of work in-house.
- Discontinued-operation losses fell sharply because the prior-year quarter included substantial inventory, personnel and facility-related charges. The current quarter primarily reflected term-loan interest and costs to maintain the CDMO facility.
- The company issued approximately 7.0 million common shares during the quarter, including 3.42 million shares through its ATM program and 3.62 million shares to Lincoln Park, raising approximately $2.9 million before or inclusive of reported issuance costs as applicable.
- Existing Series A and Series B warrant exercise prices were reduced from $1.04 to $0.50 per share for specified warrant holders, increasing potential dilution.
- The CDMO facility and related assets remained classified as held for sale at approximately $18.1 million. The company had previously agreed to sell the facility for $17.25 million, but the buyer terminated the agreement on November 7, 2023.
Guidance, Outlook, Risks and Unusual Items
- Management states that substantial doubt exists regarding the company’s ability to continue as a going concern for at least 12 months from the filing date. Current resources were not expected to fund operations through December 31, 2023 without additional financing, further cost reductions or a facility sale.
- The $12.6 million Woodforest term loan matured, or was scheduled to mature, on December 31, 2023. Management stated that it was unlikely to have sufficient funds to repay the loan if the facility was not sold by that date. The debt is secured by the CDMO facility and other iBio CDMO assets, and iBio, Inc. is a guarantor.
- Following the buyer’s termination, the facility remained listed for sale with no identified buyer. Management estimated potential net proceeds of approximately $16.1 million based on an expected sale price of approximately $17.0 million less selling costs, but disclosed that a further material impairment could result if the facility is not sold for the expected amount.
- The company raised additional equity capital during and after the quarter, but these financings caused substantial dilution. The Lincoln Park agreement permits potential additional common-stock sales of up to $10 million, subject to conditions and limitations.
- Management expects continued operating losses and does not anticipate significant product revenue for several years, if ever. Future funding alternatives include equity offerings, asset sales, out-licensing, collaborations, grants and additional cost reductions.
- IBIO-101’s $5.0 million indefinite-lived intangible asset was tested for impairment and was not impaired as of September 30, 2023, but management considers it at risk of future impairment due to stock-price, market, competitive and development uncertainties.
- The company ceased CDMO operations and reduced its workforce by approximately 60%, or about 69 positions, beginning in fiscal 2023.
- Management reported effective disclosure controls as of September 30, 2023 and no material changes in internal control over financial reporting during the quarter. No material legal proceedings were reported.
Most Important Facts for Investors to Verify
- Whether the Woodforest term loan was repaid, refinanced, amended or accelerated after its December 31, 2023 maturity date.
- Whether the CDMO facility was sold, at what price and with what net proceeds, and whether additional impairment or foreclosure risk arose.
- The company’s actual unrestricted cash balance and cash burn after the filing date, including the availability of restricted cash.
- Additional equity issuances, warrant exercises, commitment shares and the resulting fully diluted share count.
- Whether new collaborations, licensing transactions or other non-dilutive funding generate meaningful revenue or extend the cash runway.
- Progress toward IBIO-101 IND-enabling work and the stated 2025 IND filing objective, as well as advancement of the other preclinical programs.
- Potential impairment of the IBIO-101 intangible asset and other held-for-sale assets.